Roche's New Chief Medical Officer Levi Garraway Brings Deep Cancer Genomics Expertise
Executive Summary
CMO Sandra Horning will retire at the end of the year, to be succeeded by Lilly's former senior VP of oncology R&D on 1 October.
You may also be interested in...
Lilly Taps Loxo Execs To Bring Back That Biotech Feeling
Almost a year after acquiring Loxo Oncology, Lilly is combining its Lilly Research Laboratories staff with a group headed by three top Loxo execs to lead cancer R&D and business development.
Bucking Biosimilar Threat, Roche Sees Further Growth
Many new and pipeline products were highlighted at London meeting – but no word on Spark Therapeutics deal. New products will have high profit margins.
Roche/Genentech Set Lower Rozlytrek Price To Catch Up With Bayer’s Vitrakvi
Entrectinib clinched double approvals in the US for ROS1-positive NSCLC and for tumors with NTRK gene fusions – making it the third tumor-agnostic and second NTRK-fusion approval in the US.